retatrutide fat loss clinical trial results 🚨 TRIUMPH-1 Phase 3 top-line results, much awaited and just announced ⬇️ 28.3% Weight at 80 weeks ⬇️ 30.3% weight loss at 104 weeks among adults with baseline BMI >35 Retatrutide NEW Phase 3 Clinical

Association of a functional polymorphism in the cholesteryl ester transfer protein (CETP) gene with memory decline and incidence of dementia

Patients requiring multifactorial risk management : Individuals with multiple cardiovascular risk factors may benefit from the pleiotropic effects of GLP-1 therapy, including blood pressure reduction, weight loss, and lipid improvements

Some programs include syringes and alcohol swabs

Retatrutide Clinical Trials Retatrutide is currently in phase III clinical trials, which are the final step before potential approval

Cohort entry was defined as the date of the first-ever prescription for one of the drugs of interest (GLP-1RAs, SGLT2 inhibitors, metformin or other second- or third-line glucose-lowering drugs) during the study period, and their respective first exposure was defined as the index event